Site icon pharmaceutical daily

China Biopharma, Clinical Development, CRO Utilization and Outlook Report 2023: Groundbreaking Insights into Clinical Development Trends, Activity, Budget Growth and Preferences – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chinese Biopharma, Clinical Development, CRO Utilization and Outlook 2023” report has been added to ResearchAndMarkets.com’s offering.

This report takes a deep dive into the Chinese innovative biopharmaceutical market, providing groundbreaking insights into clinical development trends, activity, budget growth and preferences.

The report also details clinical development outsourcing preferences and practices to local and global Contract Research Organizations (CROs) and discusses the implications on future growth of the market. This highly strategic research should be considered foundational information for CROs, analysts and investors competing and following the evolving market.

The report examines perceptions of 101 professionals at domestic, Chinese innovative biopharmaceutical companies involved in clinical development and outsourcing to local and global Contract Research Organizations (CROs).

Topics covered include:

Key Topics Covered:

I. Study Background

II. Key Conclusions and LSSG Discussion

III. Methodology

IV. Detailed Findings

V. Respondent Demographics

VI. About the Publisher, LLC

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/adhsya

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version